| 查看: 616 | 回复: 3 | |||
[交流]
求高人帮翻译一段说明书 急~
|
|||
|
1 General Responding patients may not experience an improvement in performance status on therapy and may experience worsening. The relationship between changes in performance status, response to therapy, and treatment-related side effects has not been established. 2 Cutaneous Localized erythema of the extremities with edema followed by desquamation has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended [see Dose Adjustments During Treatment (2.7)]. The discontinuation rate due to skin toxicity was 1.6% (15/965) for metastatic breast cancer patients. Among 92 breast cancer patients premedicated with 3-day corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued TAXOTERE due to skin toxicity. 3 Fluid Retention Severe fluid retention has been reported following TAXOTERE therapy [see Boxed Warning, Premedication Regimen (2.6)]. Patients should be premedicated with oral corticosteroids prior to each TAXOTERE administration to reduce the incidence and severity of fluid retention [see Premedication Regimen (2.6)]. Patients with pre-existing effusions should be closely monitored from the first dose for the possible exacerbation of the effusions. When fluid retention occurs, peripheral edema usually starts in the lower extremities and may become generalized with a median weight gain of 2 kg. Among 92 breast cancer patients premedicated with 3-day corticosteroids, moderate fluid retention occurred in 27.2% and severe fluid retention in 6.5%. The median cumulative dose to onset of moderate or severe fluid retention was 819 mg/m2. 9.8% (9/92) of patients discontinued treatment due to fluid retention: 4 patients discontinued with severe fluid retention; the remaining 5 had mild or moderate fluid retention. The median cumulative dose to treatment discontinuation due to fluid retention was 1021 mg/m2. Fluid retention was completely, but sometimes slowly, reversible with a median of 16 weeks from the last infusion of TAXOTERE to resolution (range: 0 to 42+ weeks). Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). 4 Neurologic Severe neurosensory symptoms (paresthesia, dysesthesia, pain) were observed in 5.5% (53/965) of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%. When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued [see Dose Adjustments During Treatment (2.7)]. Patients who experienced neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 9 weeks from onset (range: 0 to 106 weeks). Severe peripheral motor neuropathy mainly manifested as distal extremity weakness occurred in 4.4% (42/965). 5 Asthenia Severe asthenia has been reported in 14.9% (144/965) of metastatic breast cancer patients but has led to treatment discontinuation in only 1.8%. Symptoms of fatigue and weakness may last a few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease. 6. ADVERSE REACTIONS Adverse reactions are described for TAXOTERE according to indication. 6.1 Clinical Trial Experience • Breast Cancer Monotherapy with TAXOTERE for locally advanced or metastatic breast cancer after failure of prior chemotherapy TAXOTERE 100 mg/m2: Adverse drug reactions occurring in at least 5% of patients are compared for three populations who received TAXOTERE administered at 100 mg/m2 as a 1-hour infusion every 3 weeks: 2045 patients with various tumor types and normal baseline liver function tests; the subset of 965 patients with locally advanced or metastatic breast cancer, both previously treated and untreated with chemotherapy, who had normal baseline liver function tests; and an additional 61 patients with various tumor types who had abnormal liver function tests at baseline. These reactions were described using COSTART terms and were considered possibly or probably related to TAXOTERE. At least 95% of these patients did not receive hematopoietic support. The safety profile is generally similar in patients receiving TAXOTERE for the treatment of breast cancer and in patients with other tumor types (See Table 4). |
回复此楼» 猜你喜欢
欢迎发来filecode的Mz6后的代码验证其规律
已经有69人回复
-
有时候，自然基金真的不能太认真 （我的申报经验）
已经有11人回复
-
时间戳又变了8-15
已经有23人回复
-
filecode=后面第一个是大写字母
已经有7人回复
-
filecode
已经有12人回复
-
小木虫上这么多卖论文的，真有人买论文么？感觉没必要啊
已经有13人回复
-
哪位老哥知道今年的国自然具体哪一天放榜？
已经有7人回复
-
关于Filecode分析方法
已经有13人回复
-
各位道友，我要去昆明玩几天，回来见。
已经有8人回复
-
咱们一起用铁证分析2026国家社科基金中标与否
已经有22人回复
» 抢金币啦！回帖就可以得到:
-
北京信息科技大学机电工程学院硕士研究生招生线上宣讲会-8月16日
+5/255
-
上海一恒贝茵公司全国均可联系销售或售后服务
+1/246
-
原创销售写了20年终于完结发表
+1/222
-
上海男征女 条件优秀可加微信联系
+1/164
-
广西大学 化学化工学院 新入职教师招生 化学、化学工程与技术、材料化工专业
+1/48
-
加拿大/英属哥伦比亚大学曹彦凯课题组招收全奖博士/博后 [机器人/控制方向]
+1/36
-
清华大学深圳国际研究生院招聘-博士后（长期有效）
+1/29
-
华南理工大学招2027年生物材料、药物递送申请考核制博士生
+1/29
-
物理学报录用，散币感谢合作者和审稿人
+2/28
-
祈福
+1/21
-
北理工集成电路杰青团队 | 诚招科助理
+1/14
-
西北工业大学 生科院 秦绪军课题组诚招博士后、博士/硕士研究生【长期有效】
+1/13
-
27级博士生 + 福州大学 + 经管学院 + 管理科学与工程（见贴则有指标）
+1/9
-
27推免-广州医科大学封红亮教授招收精神医学应用心理学推免生
+1/5
-
南京医科大学-冯璋课题组-招收2027级生化与分子生物学专业博士和硕士研究生
+1/4
-
中国科学院生物物理研究所田勇课题组招聘联合培养生
+1/3
-
海南大学化学院—功能分子器件团队2027博士招生+博士后招聘
+1/2
-
KFUPM Turki Baroud组招全奖博士/博后｜下一代膜材料・水凝胶・清洁水
+1/2
-
悉尼科技大学（QS 第87）数据科学/AI招收2027年秋季入学全奖及CSC博士生
+1/1
-
国家级人才团队诚聘生物信息相关专业的科研助理
+1/1
3楼2011-04-06 14:46:32
这么长 4楼2011-04-06 15:01:20
简单回复
Mally892楼
2011-04-01 16:57
回复
suibowen2010(金币+1, 翻译EPI+1): 嘿嘿 没有办法啊 任务...看的不是很到位 很多话不知道怎么说 所以才来这求助高人啊~ 2011-04-01 19:48:04
ringzhu(翻译EPI-1): 无效应助 2011-04-06 12:41:16
哇！ringzhu(翻译EPI-1): 无效应助 2011-04-06 12:41:16
